"Shares of Kenvue Inc. ( KVUE), the parent company of Tylenol, are down around 6% in midday trading on Monday on news the Trump administration is expected to link the over-the-counter pain relief medicine to autism. According to MSNBC, there is growing alarm in the medical community ahead of an expected announcement after Trump told reporters he believed Tylenol was "a very big factor" in autism risk."
"According to a number of publications, including the Washington Post, federal health officials on Monday are expected to raise concerns about pregnant women using acetaminophen based on research-including an August review by Mount Sinai and Harvard-suggesting a potential link between Tylenol use in early pregnancy and an increased risk of autism in children. However, it is important to note that Tylenol is generally considered safe to use and generally not linked to autism."
Kenvue shares fell about 6% in midday trading after reports that the Trump administration is expected to link the over-the-counter pain reliever Tylenol (acetaminophen) to autism. Federal officials are reportedly preparing warnings about pregnant women using acetaminophen, citing research including an August review by Mount Sinai and Harvard suggesting a potential association between early-pregnancy use and higher autism risk. Other studies conflict; a JAMA study found no increased risk of autism, ADHD, or intellectual disability following prenatal acetaminophen exposure. Kenvue was spun off from Johnson & Johnson in 2023. Officials are also expected to discuss leucovorin as a potential autism treatment.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]